Last reviewed · How we verify
Phenergan Vc W/ Codeine (PHENYLEPHRINE BITARTRATE)
Phenergan Vc W/ Codeine is a medication developed by ANI PHARMS, targeting the alpha-1B adrenergic receptor. It belongs to the alpha-1 Adrenergic Agonist class and is a small molecule modality. Approved by the FDA in 1952, it treats various conditions including allergic conjunctivitis, allergic rhinitis, and cough. The commercial status of Phenergan Vc W/ Codeine is owned by ANI PHARMS, and its key safety considerations include potential side effects such as drowsiness and dry mouth. As an alpha-1 adrenergic agonist, it works by stimulating the alpha-1B adrenergic receptor, leading to vasoconstriction and increased blood pressure.
At a glance
| Generic name | PHENYLEPHRINE BITARTRATE |
|---|---|
| Sponsor | ANI Pharmaceuticals |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Target | Alpha-1B adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1952 |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Cough
- Dilated pupil
- Fever
- Headache disorder
- Hemorrhoids
- Influenza-like symptoms
- Maintenance of intraoperative mydriasis
- Nasal congestion
- Nasal discharge
- Postoperative ocular pain in intraocular lens replacement surgery
- Prevention of Posterior Synechiae
- Prevention of intraoperative miosis
- Proctitis
- Pruritus ani
- Rectal pain
- Red eye
- Rhinitis
Common side effects
Drug interactions
- Ioflupane I-123
- rasagiline
- tranylcypromine
Key clinical trials
- Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences (PHASE4)
- Effects of Vasopressor on the Graft Blood Flow in TRAM (NA)
- To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen (PHASE1)
- Norepinephrine Versus Phenylephrine Continuous Variable Infusion in Cesarean Delivery (PHASE4)
- A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries (NA)
- A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |